Afatinib is especially effective against non-small cell lung cancer carrying an EGFR exon 19 deletion

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Previous trials indicate afatinib's effectiveness in non-small cell lung cancer (NSCLC).
• Afatinib is an irreversible epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI).
• A pooled analysis highlighted afatinib's particular efficacy in NSCLC with EGFR exon 19 deletions.

Purpose of the Study:

• To experimentally validate afatinib's enhanced efficacy against EGFR exon 19 deletions.
• To compare the sensitivity of cells with EGFR exon 19 deletions versus exon 21 L858R mutations to afatinib and a reversible EGFR-TKI.

Main Methods:

• Created HEK293 cell lines with stable EGFR exon 19 deletion (HEK293/19 del) or exon 21 L858R mutation (HEK293/L858R).
• Assessed drug sensitivity using MTT assays for afatinib and AG1478 (reversible EGFR-TKI).
• Utilized Western blot analysis to measure epidermal growth factor receptor (EGFR) phosphorylation.

Main Results:

• Afatinib exhibited a significantly lower IC50 in HEK293/19 del cells compared to HEK293/L858R cells.
• Afatinib more potently inhibited EGFR phosphorylation in cells with the exon 19 deletion.
• These findings confirm enhanced sensitivity of EGFR exon 19 deletion mutations to afatinib.

Conclusions:

• Afatinib is particularly effective against non-small cell lung cancer (NSCLC) harboring an EGFR exon 19 deletion.
• The study provides experimental evidence supporting afatinib's targeted efficacy.
• This supports the use of afatinib in NSCLC patients with specific EGFR mutations.